2024-04-02 23:00:23
[딜사이트 최광석 기자] Attention is growing on the future actions of Hanmi Pharmaceutical Group, which has settled the management rights dispute. This is because former Hanmi Pharmaceutical President Lim Jong-yoon, who holds the majority of the board of directors, expressed his ambition to change the company’s main field from synthetic (chemical) drugs to biopharmaceuticals. For this purpose, we plan to initially pour in financial resources amounting to 1 trillion won. The market predicts that smoothly attracting investment funds to promote the biopharmaceutical business will be the key to the success or failure of a new business.
According to the industry on the 2nd, former CEO Lim plans to focus on the biopharmaceutical business to improve the profitability of Hanmi Pharmaceutical Group in the future. His goal is to enter the contract development (CDO) and contract clinical trial (CRO) fields and make the Hanmi Pharmaceutical Group into Korea’s ‘Lonagonist’. Lonza is the world’s No. 1 contract development and manufacturing (CDMO) company located in Switzerland.
To this end, former CEO Lim plans to build a bio factory following attracting more than 1 trillion won in investment. The detailed direction has not yet been revealed, but small-scale production of a variety of products is likely. The strategy is to use CDO and CRO as future growth engines rather than the contract manufacturing (CMO) method like Samsung BioLogics. In addition, the innovative new drug development pipeline that has been promoted so far will be expanded.
Former CEO Lim initially announced a vision for a market capitalization of 50 trillion won with the goal of producing more than 100 biopharmaceuticals. Ultimately, the ambition is to grow Hanmi Pharmaceutical Group to 200 trillion won. He explained that he has already completed planning and design for the establishment of a Pandemic Science Center with world-class pharmaceutical manufacturing and quality management (GMP) experts in 2021 to produce 100 biopharmaceuticals. However, it is difficult to disclose detailed technology and strategy at this time.
The key is to raise financing worth 1 trillion won to build a biopharmaceutical production base. Former CEO Lim even threatened to step down if the biopharmaceutical business fails following attracting investment.
The market predicts that various methods will be used to raise funds. First, it is a method of raising funds from investment companies such as private equity funds. It is also possible to receive a loan using Hanmi Pharmaceutical Group’s own stocks as collateral or to attract funds through an initial public offering (IPO) of an unlisted affiliate, Online Farm.
In addition, the possibility of raising funds through the IPO or sale of old shares of COREE Group, owned by former President Jong-yoon Lim, cannot be ruled out. Corey Group is a research and development (R&D) and bio-healthcare technology investment company established in Hong Kong in 2009 by former CEO Lim Jong-yoon.
A DXVX official briefly answered, “We are open and reviewing various possibilities related to attracting investment.” DXVX is a bio-healthcare company in which former CEO Lim Jong-yoon is the largest shareholder. Former President Lim’s stake is 19.25% (5,816,189 shares).
Meanwhile, it is reported that Hanmi Science, the holding company of Hanmi Pharmaceutical Group, will hold a board meeting this week to discuss future management plans. In particular, at this board meeting, it is expected that Lim Jong-hoon, former president of Hanmi Pharmaceutical, will be appointed CEO of Hanmi Science, and former President Jong-yoon Lim will be appointed CEO of Hanmi Pharmaceutical, according to the shareholder proposal announced in February of this year.
ⓒLooking at the market with new eyes. Deal site unauthorized reproduction prohibited
1712103634
#Korean #Lonzas #Goal #Hanmi #Pharmaceutical #raise #KRW #trillion #financing
